Rising Pharma Recalls Duloxetine DR Capsules Nationwide Over N-nitroso-duloxetine Impurity and CGMP Deviations
Rising Pharma Holding, Inc. has initiated a Class II nationwide recall of 233,003 bottles of Duloxetine DR Capsules USP 60 mg due to N-nitroso-duloxetine impurity exceeding interim limits. This CGMP deviation highlights critical quality control failures, posing significant supply chain and regulatory compliance risks for procurement and regulatory affairs teams sourcing similar active pharmaceutical ingredients.
Immediate Regulatory Action: Rising Pharma's Nationwide Duloxetine Recall
On November 19, 2024, Rising Pharma Holding, Inc., based in East Brunswick, NJ, initiated a voluntary, firm-initiated Class II recall of its Duloxetine DR Capsules USP 60 mg. This significant regulatory event impacts 233,003 bottles distributed nationwide across the United States. The recall, identified as D-0107-2025, encompasses multiple batch codes and expiration dates, including those expiring in January, February, March, April, August, October, November, and December 2025, as well as November and December 2024. This action by Rising Pharma Holding, Inc. underscores the critical importance of stringent quality control throughout the pharmaceutical supply chain. For procurement directors and supply chain VPs, this recall necessitates an immediate review of current inventory and distribution networks to identify and quarantine affected product lots. The Class II classification indicates that the use of or exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification demands prompt action to protect patient safety and maintain market integrity, directly impacting business continuity and brand reputation.
The Core Violation: N-nitroso-duloxetine Impurity and CGMP Deviations
The fundamental reason behind this extensive recall is the presence of N-nitroso-duloxetine impurity, which was found to be above the FDA's recommended interim limit. This constitutes a critical Current Good Manufacturing Practice (CGMP) deviation. Nitrosamine impurities, including N-nitroso-duloxetine, are a class of compounds recognized as probable human carcinogens, and their presence in pharmaceutical products at levels exceeding established safety thresholds is a serious regulatory concern. For regulatory affairs heads, this event highlights the ongoing scrutiny by the FDA regarding nitrosamine contamination across various drug products. The identification of N-nitroso-duloxetine above interim limits suggests a breakdown in Rising Pharma Holding, Inc.'s manufacturing process controls, raw material qualification, or stability monitoring programs. Businesses must ensure their quality management systems are robust enough to detect and control such impurities, not just in finished products but throughout the entire manufacturing lifecycle, from API synthesis to final formulation. Failure to adhere to these CGMP standards can lead to costly recalls, market withdrawals, and significant reputational damage, directly impacting profitability and market access.
Supply Chain and Market Impact of Duloxetine Disruption
The recall of Duloxetine DR Capsules USP 60 mg by Rising Pharma Holding, Inc. has immediate and tangible implications for the nationwide supply chain. The affected product is distributed in 30-count (NDC 57237-019-30), 90-count (NDC 57237-019-90), and 1000-count (NDC 57237-019-99) bottles, indicating widespread availability across various pharmacy and healthcare settings. With 233,003 bottles impacted, this event could lead to localized shortages or increased demand on alternative suppliers of duloxetine, a critical medication used for major depressive disorder, generalized anxiety disorder, and neuropathic pain. Procurement directors must assess their existing contracts and inventory levels for Duloxetine DR Capsules, particularly those sourced from Rising Pharmaceuticals, Inc., the distributor in East Brunswick, NJ. The need to identify and qualify alternative suppliers becomes paramount to ensure continuity of patient care and avoid market disruption. Business development executives should monitor market dynamics closely, as this recall may create opportunities for competitors with compliant duloxetine products. Proactive engagement with regulatory teams and supply chain partners is essential to navigate the complexities introduced by such a large-scale product withdrawal and to mitigate financial and operational risks.
Broader Industry Implications: Managing Nitrosamine Risk and CGMP Compliance
The recall of Duloxetine DR Capsules due to N-nitroso-duloxetine impurity underscores a pervasive challenge facing the global pharmaceutical industry: the control of nitrosamine impurities. This is not an isolated incident but part of a broader regulatory push by agencies like the FDA to ensure drug product safety. Companies across the chemical and life sciences sectors must recognize that CGMP compliance extends beyond traditional quality parameters to include rigorous assessment and control of potential genotoxic impurities. Regulatory affairs heads should review their company's risk assessment strategies for nitrosamines, encompassing raw material sourcing, manufacturing processes, and packaging materials. This includes understanding the potential for nitrosamine formation in various chemical reactions and during storage. Investing in advanced analytical testing capabilities and implementing robust impurity control strategies are no longer optional but fundamental requirements for market access and sustained operations. The FDA's consistent enforcement actions, even for voluntary recalls initiated by firms like Rising Pharma Holding, Inc., signal a zero-tolerance approach to deviations that compromise patient safety. Proactive investment in quality systems and continuous monitoring of regulatory guidance are critical to avoid similar costly disruptions and maintain stakeholder confidence.